An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

Study Purpose

The overall aim of this project is to improve the outcome of patients diagnosed with ependymoma by improving and harmonising the staging and the standard of care of this patient population and to improve the investigators understanding of the underlying biology thereby informing future treatment. The program will evaluate new strategies for diagnosis (centralized reviews of pathology and imaging) and new therapeutic strategies in order to develop treatment recommendations. Patients will be stratified into different treatment subgroups according to their age, the tumour location and the outcome of the initial surgery. Each subgroup will be studied in a specific randomised study to evaluate the proposed therapeutic strategies. Stratum 1: The aim of the stratum 1 is to evaluate the clinical impact of 16-week chemotherapy regimen with VEC-CDDP following surgical resection and conformal radiotherapy in terms of progression free survival in patients who are > 12 months and < 22 years at diagnosis, with completely removed intra cranial Ependymoma. Stratum 2: This stratum is designed as a phase II trial for patients who are > 12 months and < 22 years at diagnosis, with residual disease to investigate the possible activity of HD-MTX by giving to all patients the benefit of VEC chemotherapy whilst randomising half of patients to receive additional HD-MTX. Patients will receive conformal radiotherapy (cRT). For patients who remain with a residual inoperable disease after induction chemotherapy and cRT, an 8 Gy boost of radiotherapy to the residual tumour will be delivered immediately after the end of the cRT. Stratum 3 This stratum is designed as a phase II trial to evaluate the benefit of postoperative dose intense chemotherapy administered alone or in combination with valproate in children <12 months of age or those not eligible to receive radiotherapy .

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages N/A - 22 Years
Gender All
More Inclusion & Exclusion Criteria

After Initial surgery, patients will be enrolled in one of 3 different interventional strata where they will be offered a set of therapeutic interventions based on the outcome of the intervention (no measurable residue vs.residual inoperable disease), their age and/or their eligibility /suitability to receive radiotherapy. Patients with centrally and histologically confirmed intracranial ependymoma meeting the following criteria will be enrolled into one of interventional stratum:

  • - Age < 22 years old at diagnosis.
  • - Newly diagnosed with an ependymoma WHO grade II and III, including ependymoma variants: papillary, clear-cell and tanycytic, RELA fusion positive or anaplastic ependymoma.
  • - Post-menarchal female not pregnant or nursing (breast feeding) and with a negative beta-HCG pregnancy test prior to commencing the trial.
  • - Males and females of reproductive age and childbearing potential with effective contraception for the duration of their treatment and 6 months after the completion of their treatment.
  • - No contraindication to the use if one of the study drugs proposed by the protocol.
  • - Patients and/or their parents or legal guardians willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedure.
Common inclusion criteria for Strata 1 and 2:
  • - Age > 12 months and < 22 years at time of study entry.
  • - Histologically confirmed WHO Grade II-III ependymoma by central pathological review.
  • - No metastasis on spinal MRI and on CSF cytology assessments.
  • - No previous radiotherapy.
  • - No previous chemotherapy (except steroids) - No co-existent unrelated disease at the time of study entry that would render the patient unable to receive chemotherapy.
  • - No medical contraindication to radiotherapy and chemotherapy.
  • - No signs of infection.
  • - Adequate bone marrow, liver and renal functions.
Specific inclusion criteria for Stratum 1: • No residual measurable ependymoma based on the central neuroradiological review (R0-1-2) Specific inclusion criteria for Stratum 2: • Residual non reoperable measurable ependymoma based on the central neuroradiological review (R3-4) Inclusion criteria for Stratum 3:
  • - Children younger than 12 months at time of entry to study or any children ineligible to receive radiotherapy due to age at diagnosis, tumour location or clinician / parent decision and according to national criteria.
  • - Histologically confirmed WHO Grade II-III ependymoma by central pathological review.
  • - Adequate bone marrow, liver and renal functions.
  • - No previous chemotherapy and radiotherapy.
  • - No contraindication to chemotherapy.
  • - No co-existent unrelated disease at the time of study entry that would render the patient unable to receive chemotherapy.
  • - No signs of infection.
Patients that do not fulfill the inclusion criteria of one of the interventional strata will be enrolled and followed up into an observational study and descriptive analysis will be performed. EXCLUSION CRITERIA for all interventional strata:
  • - Tumour entity other than primary intracranial ependymoma.
  • - Primary diagnosis predating the opening of SIOP Ependymoma II.
  • - Patients with WHO grade I ependymoma including ependymoma variants: myxopapillary ependymomas and subependymomas,patients with spinal cord location of the primary tumour.
  • - Participation within a different trial for treatment of ependymoma.
  • - Contraindication to one of the IMP used according to the SmPCs.
  • - Concurrent treatment with any anti-tumour agents.
  • - Inability to tolerate chemotherapy.
  • - Unable to tolerate intravenous hydration.
  • - Pre-existing mucositis, peptic ulcer, inflammatory bowel disease ascites, or pleural effusion.
Strata 1 and 2:
  • - Ineligible to receive radiotherapy.
  • - Patient for whom imaging remains RX despite all effort to clarify the MRI conclusion.
Stratum 3:
  • - Pre-existing severe hepatic and/or renal damage.
  • - Family history of severe epilepsy.
  • - Presence of previously undiagnosed mitochondrial disorder detected by screening as part of trial.
- Elevated blood ammonium and lactate level ≥ 1.5 x upper limit of the normal

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02265770
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2/Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Centre Leon Berard
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Pierre LEBLOND, MD
Principal Investigator Affiliation IHOP
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries Austria, Belgium, Czechia, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Childhood Ependymoma
Additional Details

The Ependymoma Program is a comprehensive program to improve the accuracy of the primary diagnosis of ependymoma and explore different therapeutic strategies in children, adolescents and young adults, accordingly. This program is opened to all patients diagnosed with ependymoma below the age of 22 years. It will include a centralised review of pre and post-operative imaging to assess the completeness of the resection. It will also include a central review of pathology to confirm the histological diagnosis. The biological markers 1q gain, Tenascin C status, NELL2 and LAMA2, RELA-fusion and molecular subgroup by methylation array will be prospectively assessed for prospective evaluation of disease subgroups. Further biological evaluations will be coordinated within the linked BIOMECA study. After surgery and central review of imaging and pathology, patients will be offered the opportunity to undergo second look surgery, if possible. Patients will be enrolled in one of 3 different strata according to the outcome of the initial surgical resection (residual disease vs.#46;no residual disease), their age or eligibility / suitability to receive radiotherapy. These 3 different strata correspond to 3 therapeutic strategies according to the patient status. 1. Stratum 1 is designed as a randomised phase III study for patients who have had a complete resection, with no measurable residual disease (as confirmed by centrally reviewed MRI) and are > 12 months and < 22 years at diagnosis. Those patients will be randomised to receive conformal radiotherapy followed by either 16 weeks of chemotherapy with VEC-CDDP, or observation. 2. Stratum 2 is designed as a randomised phase II study for patients who have inoperable measurable residual disease and who are > 12 months and < 22 years at diagnosis. Those patients will be randomised to two different treatment schedules of chemotherapy either with VEC or VEC+ high dose methotrexate (VEC +HD-MTX). After completion of the frontline chemotherapy, patients will be assessed for response (MRI) and will receive second look surgery when feasible. For those patients who remain unresectable with residual disease despite frontline chemotherapy and for whom second line surgery is not feasible, there will be a study of the safety of a radiotherapy boost of 8 Gy that will be administered to the residual tumour immediately after the completion of the conformal radiotherapy. Patients without evidence of residual disease after the chemotherapy and/or a second look surgery are not eligible for radiotherapy boost. All patients who have not shown progression under chemotherapy will receive, as maintenance therapy, a 16 week course of VEC -CDDP following completion of radiotherapy. 3. Stratum 3 is designed as a randomised phase II chemotherapy study in children <12 months of age or those not eligible to receive radiotherapy. These patients will be randomised to receive a dose dense chemotherapy alternating myelosuppressive and relatively non-myelosuppressive drugs at 2 weekly intervals, with or without, the addition of the histone deacetylase inhibitor, valproate. Registry: Patients that do not fulfil the inclusion criteria of one of the interventional strata will be enrolled and followed up via an observational study which will be analysed descriptively.

Arms & Interventions

Arms

Experimental: Stratum 1 arm A

Conformal radiotherapy followed by 16 weeks of VEC + CDDP.

Active Comparator: Stratum 1 arm B

Conformal radiotherapy.

Experimental: Stratum 2 arm A

VEC + HD-MTX followed by conformal radiotherapy +/- boost

Active Comparator: Stratum 2 arm B

VEC followed by conformal radiotherapy +/- boost

Experimental: Stratum 3 arm A

Chemotherapy + Valproate.

Active Comparator: Stratum 3 arm B

Chemotherapy

Interventions

Drug: - 16 weeks of VEC + CDDP

Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.

Drug: - VEC + HD-MTX

Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.

Drug: - Chemotherapy + Valproate

Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion. Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses.

Radiation: - Conformal radiotherapy

Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.

Drug: - VEC

D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes

Drug: - Chemotherapy

Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.

Radiation: - conformal radiotherapy +/- boost

Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week. In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Graz, Austria

Status

Recruiting

Address

Medical University of Graz-Department of Pediatrics and Adolescent Medicine

Graz, , 8036

Site Contact

Martin Benesch, MD

martin.benesch@klinikum-graz.at

+43 (0) 316/385-80427

CHR de la CITADELLE, Liege, Belgium

Status

Recruiting

Address

CHR de la CITADELLE

Liege, , 4000

Site Contact

Caroline Piette

caroline.piette@chrcitadelle.be

+32 4 225 60 97

University Hospital Brno, Brno, Czechia

Status

Recruiting

Address

University Hospital Brno

Brno, , 61300

Site Contact

Jaroslav Sterba, MD

jsterb@fnbrno.cz

+420 532 234 600/755

Aarhus University Hospital, Aarhus, Denmark

Status

Recruiting

Address

Aarhus University Hospital

Aarhus, , 8200

Site Contact

Pernille Wendtland Edslev

pernedsl@rm.dk

+45 78451701

CHRU STRASBOURG - Hôpital de Hautepierre, Strasbourg, Bas-Rhin, France

Status

Recruiting

Address

CHRU STRASBOURG - Hôpital de Hautepierre

Strasbourg, Bas-Rhin, 67098

Site Contact

Natacha Entz-Werle, MD

natacha.entz-werle@chru-strasbourg.fr

+33 3 88 12 83 96

AP-HM - Hôpital d'Enfants de La Timone, Marseille, Bouches-du-Rhône, France

Status

Recruiting

Address

AP-HM - Hôpital d'Enfants de La Timone

Marseille, Bouches-du-Rhône, 13385

Site Contact

Jean-Claude Gentet, MD

jean-claude.gentet@ap-hm.fr

+33 4 91 38 68 21

CHU Dijon - Hôpital des Enfants, Dijon, Côte d'Or, France

Status

Recruiting

Address

CHU Dijon - Hôpital des Enfants

Dijon, Côte d'Or, 21079

Site Contact

Claire Briandet, MD

claire.briandet@chu-dijon.fr

03 80 29 34 14 #+33

CHRU BESANCON - Hôpital Jean Minjoz, Besançon, Doubs, France

Status

Recruiting

Address

CHRU BESANCON - Hôpital Jean Minjoz

Besançon, Doubs, 25030

Site Contact

Véronique Laithier, MD

vlaithier@chu-besançon.fr

+33 3 81 66 81 66

CHRU BREST - Hôpital Morvan, Brest, Finistère, France

Status

Recruiting

Address

CHRU BREST - Hôpital Morvan

Brest, Finistère, 29609

Site Contact

Liana-Stefania Carausu, MD

liana.carausu@chu-brest.fr

+33 2 98 22 33 81

Bordeaux, Gironde, France

Status

Recruiting

Address

CHU de Bordeaux-Hôpital des enfants Pellegrin

Bordeaux, Gironde, 33000

Site Contact

Céline Icher, MD

celine.icher@chu-bordeaux.fr

+33 5 57 82 04 34

CHU de TOULOUSE - Hôpital des Enfants, Toulouse, Haute-Garonne, France

Status

Recruiting

Address

CHU de TOULOUSE - Hôpital des Enfants

Toulouse, Haute-Garonne, 31059

Site Contact

Anne-Isabelle Bertozzi-Salamon, MD

bertozzi.ai@chu-toulouse.fr

+33 5 34 55 86 13

Montpellier, Herault, France

Status

Recruiting

Address

CHRU MONTPELLIER - Hôpital Arnaud de Villeneuve

Montpellier, Herault, 34295

Site Contact

Nicolas Sirvent, MD

n-sirvent@chu-montpellier.fr

+33 4 67 33 65 19

Fondation Institut Curie, Paris, Ile-De-France, France

Status

Recruiting

Address

Fondation Institut Curie

Paris, Ile-De-France, 75005

Site Contact

François Doz, MD

francois.doz@curie.fr

+33 1 44 32 46 01

Institut Gustave Roussy, Villejuif, Ile-de-France, France

Status

Recruiting

Address

Institut Gustave Roussy

Villejuif, Ile-de-France, 94805

Site Contact

Léa Guérrini-Rousseau, MD

lea.guerrini-rousseau@gustaveroussy.fr

+33 1 42 11 42 11

CHU de RENNES - Hôpital Sud, Rennes, Ille-et-Vilaine, France

Status

Recruiting

Address

CHU de RENNES - Hôpital Sud

Rennes, Ille-et-Vilaine, 35203

Site Contact

Charline Normand, MD

charline.normand@chu-rennes.fr

+33 2 99 26 58 35

CHRU Tours - Hôpital Clocheville, Tours, Indre-et-Loire, France

Status

Recruiting

Address

CHRU Tours - Hôpital Clocheville

Tours, Indre-et-Loire, 37044

Site Contact

Pascale Blouin, MD

p.blouin@chu-tours.fr

02 47 47 49 72 #+33

CHU GRENOBLE - Hôpital Couple-Enfant, La Tronche, Isère, France

Status

Recruiting

Address

CHU GRENOBLE - Hôpital Couple-Enfant

La Tronche, Isère, 38700

Site Contact

Anne Pagnier, MD

apagnier@chu-grenoble.fr

+33 4 76 76 54 69

CHRU Saint-Etienne, Saint-Etienne, Loire, France

Status

Recruiting

Address

CHRU Saint-Etienne

Saint-Etienne, Loire, 42055

Site Contact

Sandrine Thouvenin, MD

sandrine.thouvenin@chu-st-etienne.fr

04 77 82 88 08 #+33

Chu Angers, Angers, Maine-et-Loire, France

Status

Recruiting

Address

Chu Angers

Angers, Maine-et-Loire, 49100

Site Contact

Emilie De Carli, MD

EmDecarli@chu-angers.fr

+33 2 41 35 38 63

CHU REIMS - American Memorial Hospital, Reims, Marne, France

Status

Recruiting

Address

CHU REIMS - American Memorial Hospital

Reims, Marne, 51092

Site Contact

Claire Pluchart, MD

cpluchart@chu-reims.fr

+33 4 69 16 66 14

CHU NANCY - Brabois Hôpital d'Enfants, Vandoeuvre-les-Nancy, Meurthe-et-Moselle, France

Status

Recruiting

Address

CHU NANCY - Brabois Hôpital d'Enfants

Vandoeuvre-les-Nancy, Meurthe-et-Moselle, 54511

Site Contact

Pascal Chastagner, MD

p.chastagner@chu-nancy.fr

+33 3 83 15 46 37

Centre OSCAR LAMBRET, Lille, Nord, France

Status

Recruiting

Address

Centre OSCAR LAMBRET

Lille, Nord, 59000

Site Contact

Hélène SUDOUR, MD

h-sudour@o-lambret.fr

+33 3 20 29 59 56

CHU Clermont- Ferrand - Hôpital Estaing, Clermont-Ferrand, Puy-de-Dôme, France

Status

Recruiting

Address

CHU Clermont- Ferrand - Hôpital Estaing

Clermont-Ferrand, Puy-de-Dôme, 63003

Site Contact

Catherine Paillard, MD

cpaillard@chu-clermontferrand.fr

+33 4 73 75 00 09

Centre LEON BERARD, Lyon, Rhône, France

Status

Recruiting

Address

Centre LEON BERARD

Lyon, Rhône, 69473

Site Contact

Pierre LEBLOND, MD

pierre.leblond@lyon.unicancer.fr

+33 4 69 16 66 14

CHU Rouen - Hôpital Charles Nicolle, Rouen, Seine Maritime, France

Status

Recruiting

Address

CHU Rouen - Hôpital Charles Nicolle

Rouen, Seine Maritime, 76031

Site Contact

Pascale Schneider, MD

pascale.schneider@chu-rouen.fr

02 32 88 81 91 #+33

CHU AMIENS-PICARDIE - Hôpital Nord, Amiens, Somme, France

Status

Recruiting

Address

CHU AMIENS-PICARDIE - Hôpital Nord

Amiens, Somme, 80054

Site Contact

Catherine Devoldere, MD

devoldere.catherine@chu-amiens.fr

+33 3 22 66 89 50

CHU POITIERS - Hôpital de la Milétrie, Poitiers, Vienne, France

Status

Recruiting

Address

CHU POITIERS - Hôpital de la Milétrie

Poitiers, Vienne, 86021

Site Contact

Frédéric Millot, MD

f.millot@chu-poitiers.fr

+33 5 49 44 30 78

CHU Limoges, Limoges, France

Status

Recruiting

Address

CHU Limoges

Limoges, ,

Site Contact

Christophe Piguet, MD

christophe.piguet@chu-limoges.fr

+33 5 55 05 68 01

CHU Nice - Hôpital de l'Archet 2, Nice, France

Status

Recruiting

Address

CHU Nice - Hôpital de l'Archet 2

Nice, , 06202

Site Contact

Christine SOLER, MD

soler.c@chu-nice.fr

+33492039268

CHU La Réunion, Saint-Denis, France

Status

Recruiting

Address

CHU La Réunion

Saint-Denis, , 97400

Site Contact

Yves REGUERRE, MD

Yves.reguerre@chu-reunion.fr

+33 4 69 16 66 14

Hamburg, Germany

Status

Recruiting

Address

University Medical Center Hamburg-Eppendorf

Hamburg, , 20246

Site Contact

Stefan Rutkowski, MD

s.rutkowski@uke.de

+33 4 69 16 66 14

Our Lady's Children's Hospital, Dublin, Ireland

Status

Recruiting

Address

Our Lady's Children's Hospital

Dublin, ,

Site Contact

Michael Capra, MD

Michael.capra@olhsc.ie

+353 1 409 6659

Milan, Italy

Status

Recruiting

Address

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, , 20133

Site Contact

Maura Massimino, MD

Maura.Massimino@istitutotumori.mi.it

+39 0223902593

Utrecht, Netherlands

Status

Recruiting

Address

Princess Maxima Center for pediatric oncology

Utrecht, ,

Site Contact

Jasper van der Lugt, MD

J.vanderLugt@prinsesmaximacentrum.nl

+31 6 1855 96 94

Bergen, Norway

Status

Recruiting

Address

Department of Paediatric, Haukeland University Hospital

Bergen, , 5021

Site Contact

Ingrid Kristin Torsvik, MD, PhD

Ingrid.kristin.torsvik@helse-bergen.no

+47 5597 5199

University Medical Center Ljubljana, Ljubljana, Slovenia

Status

Not yet recruiting

Address

University Medical Center Ljubljana

Ljubljana, , 1000

Site Contact

Lidija Kitanovski, MD

lidija.kitanovski@kclj.si

+ 386 1 522 9215 / 522 9256

Sevilla, Spain

Status

Recruiting

Address

Hospitales Universitarios Virgen Macarena y Virgen del Rocío Avda

Sevilla, , 41071

Site Contact

Ana Fernández-Teijeiro, MD

anateijeiro@hotmail.com

+34677903132

Skåne University Hospital, Lund, Sweden

Status

Not yet recruiting

Address

Skåne University Hospital

Lund, , 22185

Site Contact

Helena Mörse, MD

Helena.Morse@skane.se

+46 46 178281

University Children's Hospital, Zurich, Switzerland

Status

Recruiting

Address

University Children's Hospital

Zurich, , 8032

Site Contact

Nicolas Gerber, MD

nicolas.gerber@kispi.uzh.ch

+41 44 266 31 17

Queen's Medical Centre, Nottingham, United Kingdom

Status

Recruiting

Address

Queen's Medical Centre

Nottingham, ,

Site Contact

Richard Grundy, MD

richard.grundy@nottingham.ac.uk

+44 115 8230620

Stay Informed & Connected